Propagation of tau pathology in Alzheimer's disease: Identification of novel therapeutic targets

Alzheimer's Research and Therapy

Volumn 5, Issue 5, 2013, Pages

  Pooler, Amy M ^a,b   Polydoro, Manuela ^a   Wegmann, Susanne ^a   Nicholls, Samantha B ^a   Spires Jones, Tara L ^a   Hyman, Bradley T ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

PEPTIDE; PROTEIN ANTIBODY; TAU PEPTIDE; TAU PROTEIN; TAU PROTEIN ANTIBODY; UNCLASSIFIED DRUG;

ACTIVE IMMUNIZATION; ALZHEIMER DISEASE; CELL TRANSPORT; HUMAN; INTERNALIZATION; MOLECULAR DYNAMICS; NERVE CELL; NERVE DEGENERATION; NEUROPATHOLOGY; NONHUMAN; PASSIVE IMMUNIZATION; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN SECRETION; PROTEIN TRANSPORT; REVIEW; TAUOPATHY;

EID: 84887899657     PISSN: None     EISSN: 17589193     Source Type: Journal    
DOI: 10.1186/alzrt214     Document Type: Review

References (64)

1. Domains of tau protein, differential phosphorylation, and dynamic instability of microtubules. Trinczek B, Biernat J, Baumann K, Mandelkow EM, Mandelkow E, Mol Biol Cell 1995 6 1887 1902 10.1091/mbc.6.12.1887 8590813
2. Classification and basic pathology of Alzheimer disease. Duyckaerts C, Delatour B, Potier MC, Acta Neuropathol 2009 118 5 36 10.1007/s00401-009-0532-1 19381658
3. Tau and tauopathies. Lee G, Leugers CJ, Prog Mol Biol Transl Sci 2012 107 263 293 22482453
4. Alzheimer's disease: cell-specific pathology isolates the hippocampal formation. Hyman BT, Van Hoesen GW, Damasio AR, Barnes CL, Science 1984 225 1168 1170 10.1126/science.6474172 6474172 (Pubitemid 14029099)
5. Correlation of Alzheimer disease neuropathologic changes with cognitive status: a review of the literature. Nelson PT, Alafuzoff I, Bigio EH, Bouras C, Braak H, Cairns NJ, Castellani RJ, Crain BJ, Davies P, Del Tredici K, Duyckaerts C, Frosch MP, Haroutunian V, Hof PR, Hulette CM, Hyman BT, Iwatsubo T, Jellinger KA, Jicha GA, Kövari E, Kukull WA, Leverenz JB, Love S, Mackenzie IR, Mann DM, Masliah E, McKee AC, Montine TJ, Morris JC, Schneider JA, Sonnen JA, Thal DR, Trojanowski JQ, Troncoso JC, Wisniewski T, Woltjer RL, Beach TG, J Neuropathol Exp Neurol 2012 71 362 381 10.1097/NEN.0b013e31825018f7 22487856
6. Neuropathological stageing of Alzheimer-related changes. Braak H, Braak E, Acta Neuropathol 1991 82 239 259 10.1007/BF00308809 1759558
7. The topographical and neuroanatomical distribution of neurofibrillary tangles and neuritic plaques in the cerebral cortex of patients with Alzheimer's disease. Arnold SE, Hyman BT, Flory J, Damasio AR, Van Hoesen GW, Cereb Cortex 1991 1 103 116 10.1093/cercor/1.1.103 1822725
8. Memory-related neural systems in Alzheimer's disease: an anatomic study. Hyman BT, Van Hoesen GW, Damasio AR, Neurology 1990 40 1721 1730 10.1212/WNL.40.11.1721 2234428 (Pubitemid 20383139)
9. Inclusion formation and neuronal cell death through neuron-to-neuron transmission of alpha-synuclein. Desplats P, Lee HJ, Bae EJ, Patrick C, Rockenstein E, Crews L, Spencer B, Masliah E, Lee SJ, Proc Natl Acad Sci USA 2009 106 13010 13015 10.1073/pnas.0903691106 19651612
10. Prion-like propagation of mutant superoxide dismutase-1 misfolding in neuronal cells. Munch C, O'Brien J, Bertolotti A, Proc Natl Acad Sci USA 2011 108 3548 3553 10.1073/pnas.1017275108 21321227
11. Cellular mechanisms of protein aggregate propagation. Holmes BB, Diamond MI, Curr Opin Neurol 2012 25 721 726 10.1097/WCO.0b013e32835a3ee0 23108252
12. Cell-to-cell propagation of infectious cytosolic protein aggregates. Hofmann JP, Denner P, Nussbaum-Krammer C, Kuhn PH, Suhre MH, Scheibel T, Lichtenthaler SF, Schatzl HM, Bano D, Vorberg IM, Proc Natl Acad Sci USA 2013 110 5951 5956 10.1073/pnas.1217321110 23509289
13. Prion-like propagation of protein aggregation and related therapeutic strategies. Kaufman SK, Diamond MI, Neurotherapeutics 2013 10 371 382 10.1007/s13311-013-0196-3 23801258
14. CaMKII activation in the entorhinal cortex disrupts previously encoded spatial memory. Yasuda M, Mayford MR, Neuron 2006 50 309 318 10.1016/j.neuron.2006.03.035 16630840
15. Tau suppression in a neurodegenerative mouse model improves memory function. Santacruz K, Lewis J, Spires T, Paulson J, Kotilinek L, Ingelsson M, Guimaraes A, DeTure M, Ramsden M, McGowan E, Forster C, Yue M, Orne J, Janus C, Mariash A, Kuskowski M, Hyman B, Hutton M, Ashe KH, Science 2005 309 476 481 10.1126/science.1113694 16020737 (Pubitemid 40994688)
16. Human P301L-mutant tau expression in mouse entorhinal-hippocampal network causes tau aggregation and presynaptic pathology but no cognitive deficits. Harris JA, Koyama A, Maeda S, Ho K, Devidze N, Dubal DB, Yu GQ, Masliah E, Mucke L, PLoS One 2012 7 45881 10.1371/journal.pone.0045881 23029293
17. Propagation of tau pathology in a model of early Alzheimer's disease. de Calignon A, Polydoro M, Suárez-Calvet M, William C, Adamowicz DH, Kopeikina KJ, Pitstick R, Sahara N, Ashe KH, Carlson GA, Spires-Jones TL, Hyman BT, Neuron 2012 73 685 697 10.1016/j.neuron.2011.11.033 22365544
18. Trans-synaptic spread of tau pathology in vivo. Liu L, Drouet V, Wu JW, Witter MP, Small SA, Clelland C, Duff K, PLoS One 2012 7 31302 10.1371/journal.pone.0031302 22312444
19. Interneuronal transfer of human tau between Lamprey central neurons in situ. Kim W, Lee S, Jung C, Ahmed A, Lee G, Hall GF, J Alzheimers Dis 2010 19 647 664 20110609
20. Accumulation of vesicle-associated human tau in distal dendrites drives degeneration and tau secretion in an in situ cellular tauopathy model. Lee S, Kim W, Li Z, Hall GF, Int J Alzheimers Dis 2012 2012 172837 22315694
21. Hyperphosphorylation and cleavage at D421 enhance tau secretion. Plouffe V, Mohamed NV, Rivest-McGraw J, Bertrand J, Lauzon M, Leclerc N, PLoS One 2012 7 36873 10.1371/journal.pone.0036873 22615831
22. Exosome-associated tau is secreted in tauopathy models and is selectively phosphorylated in cerebrospinal fluid in early Alzheimer disease. Saman S, Kim W, Raya M, Visnick Y, Miro S, Jackson B, McKee AC, Alvarez VE, Lee NC, Hall GF, J Biol Chem 2012 287 3842 3849 10.1074/jbc.M111.277061 22057275
23. Physiological release of endogenous tau is stimulated by neuronal activity. Pooler AM, Phillips EC, Lau DH, Noble W, Hanger DP, EMBO Rep 2013 14 389 394 10.1038/embor.2013.15 23412472
24. Transmission and spreading of tauopathy in transgenic mouse brain. Clavaguera F, Bolmont T, Crowther RA, Abramowski D, Frank S, Probst A, Fraser G, Stalder AK, Beibel M, Staufenbiel M, Jucker M, Goedert M, Tolnay M, Nat Cell Biol 2009 11 909 913 10.1038/ncb1901 19503072
25. Multiple mechanisms of extracellular tau spreading in a non-transgenic tauopathy model. Le MN, Kim W, Lee S, McKee AC, Hall GF, Am J Neurodegener Dis 2012 1 316 333 23383401
26. The synaptic accumulation of hyperphosphorylated tau oligomers in Alzheimer disease is associated with dysfunction of the ubiquitin-proteasome system. Tai HC, Serrano-Pozo A, Hashimoto T, Frosch MP, Spires-Jones TL, Hyman BT, Am J Pathol 2012 181 1426 1435 10.1016/j.ajpath.2012.06.033 22867711
27. Dendritic function of tau mediates amyloid-beta toxicity in Alzheimer's disease mouse models. Ittner LM, Ke YD, Delerue F, Bi M, Gladbach A, van Eersel J, Wölfing H, Chieng BC, Christie MJ, Napier IA, Eckert A, Staufenbiel M, Hardeman E, Götz J, Cell 2010 142 387 397 10.1016/j.cell.2010.06.036 20655099
28. Interaction of endogenous tau protein with synaptic proteins is regulated by N-methyl-D-aspartate receptor-dependent tau phosphorylation. Mondragon-Rodriguez S, Trillaud-Doppia E, Dudilot A, Bourgeois C, Lauzon M, Leclerc N, Boehm J, J Biol Chem 2012 287 32040 32053 10.1074/jbc.M112.401240 22833681
29. Functional implications of the association of tau with the plasma membrane. Pooler AM, Hanger DP, Biochem Soc Trans 2010 38 1012 1015 10.1042/BST0381012 20658995
30. Tau in cerebrospinal fluid: a potential diagnostic marker in Alzheimer's disease. Arai H, Terajima M, Miura M, Higuchi S, Muramatsu T, Machida N, Seiki H, Takase S, Clark CM, Lee VM, Trojanowski JQ, Sasaki H, Ann Neurol 1995 38 649 652 10.1002/ana.410380414 7574462
31. In vivo microdialysis reveals age-dependent decrease of brain interstitial fluid tau levels in P301S human tau transgenic mice. Yamada K, Cirrito JR, Stewart FR, Jiang H, Finn MB, Holmes BB, Binder LI, Mandelkow EM, Diamond MI, Lee VM, Holtzman DM, J Neurosci 2011 31 13110 13117 10.1523/JNEUROSCI.2569-11.2011 21917794
32. Clinical utility and analytical challenges in measurement of cerebrospinal fluid amyloid-beta1-42 and tau proteins as Alzheimer disease biomarkers. Kang JH, Korecka M, Toledo JB, Trojanowski JQ, Shaw LM, Clin Chem 2013 59 903 916 10.1373/clinchem.2013.202937 23519967
33. Constitutive secretion of tau protein by an unconventional mechanism. Chai X, Dage JL, Citron M, Neurobiol Dis 2012 48 356 366 10.1016/j.nbd.2012.05. 021 22668776
34. Extracellular Tau levels are influenced by variability in Tau that is associated with tauopathies. Karch CM, Jeng AT, Goate AM, J Biol Chem 2012 287 42751 42762 10.1074/jbc.M112.380642 23105105
35. Exosomes: mediators of communication in eukaryotes. Lopez-Verrilli MA, Court FA, Biol Res 2013 46 5 11 10.4067/S0716-97602013000100001 23760408
36. Interaction of tau with the neural plasma membrane mediated by tau's amino-terminal projection domain. Brandt R, Leger J, Lee G, J Cell Biol 1995 131 1327 1340 10.1083/jcb.131.5.1327 8522593
37. Dynamic association of tau with neuronal membranes is regulated by phosphorylation. Pooler AM, Usardi A, Evans CJ, Philpott KL, Noble W, Hanger DP, Neurobiol Aging 2012 33 431 438 e427-438
38. Proteostasis of tau. Tau overexpression results in its secretion via membrane vesicles. Simon D, Garcia-Garcia E, Royo F, Falcon-Perez JM, Avila J, FEBS Lett 2012 586 47 54 10.1016/j.febslet.2011.11.022 22138183
39. Paired helical filaments from Alzheimer disease brain induce intracellular accumulation of Tau protein in aggresomes. Santa-Maria I, Varghese M, Ksiezak-Reding H, Dzhun A, Wang J, Pasinetti GM, J Biol Chem 2012 287 20522 20533 10.1074/jbc.M111.323279 22496370
40. Exosomes are released by cultured cortical neurones. Fauré J, Lachenal G, Court M, Hirrlinger J, Chatellard-Causse C, Blot B, Grange J, Schoehn G, Goldberg Y, Boyer V, Kirchhoff F, Raposo G, Garin J, Sadoul R, Mol Cell Neurosci 2006 31 642 648 10.1016/j.mcn.2005.12.003 16446100
41. Proteomic analysis of exosomes from human neural stem cells by flow field-flow fractionation and nanoflow liquid chromatography-tandem mass spectrometry. Kang D, Oh S, Ahn SM, Lee BH, Moon MH, J Proteome Res 2008 7 3475 3480 10.1021/pr800225z 18570454
42. Quantification of tau phosphorylated at threonine 181 in human cerebrospinal fluid: a sandwich ELISA with a synthetic phosphopeptide for standardization. Vanmechelen E, Vanderstichele H, Davidsson P, Van Kerschaver E, Van Der Perre B, Sjogren M, Andreasen N, Blennow K, Neurosci Lett 2000 285 49 52 10.1016/S0304-3940(00)01036-3 10788705 (Pubitemid 30224621)
43. Calcium phosphatase calcineurin influences tau metabolism. Karch CM, Jeng AT, Goate AM, Neurobiol Aging 2013 34 374 386 10.1016/j.neurobiolaging.2012.05. 003 22676853
44. Tissue-nonspecific alkaline phosphatase promotes the neurotoxicity effect of extracellular tau. Diaz-Hernandez M, Gomez-Ramos A, Rubio A, Gomez-Villafuertes R, Naranjo JR, Miras-Portugal MT, Avila J, J Biol Chem 2010 285 32539 32548 10.1074/jbc.M110.145003 20634292
45. Propagation of tau misfolding from the outside to the inside of a cell. Frost B, Jacks RL, Diamond MI, J Biol Chem 2009 284 12845 12852 10.1074/jbc.M808759200 19282288
46. Synthetic tau fibrils mediate transmission of neurofibrillary tangles in a transgenic mouse model of Alzheimer's-like tauopathy. Iba M, Guo JL, McBride JD, Zhang B, Trojanowski JQ, Lee VM, J Neurosci 2013 33 1024 1037 10.1523/JNEUROSCI.2642-12.2013 23325240
47. Brain homogenates from human tauopathies induce tau inclusions in mouse brain. Clavaguera F, Akatsu H, Fraser G, Crowther RA, Frank S, Hench J, Probst A, Winkler DT, Reichwald J, Staufenbiel M, Ghetti B, Goedert M, Tolnay M, Proc Natl Acad Sci U S A 2013 110 9535 9540 10.1073/pnas.1301175110 23690619
48. Alzheimer brain-derived tau oligomers propagate pathology from endogenous tau. Lasagna-Reeves CA, Castillo-Carranza DL, Sengupta U, Guerrero-Munoz MJ, Kiritoshi T, Neugebauer V, Jackson GR, Kayed R, Sci Rep 2012 2 700 23050084
49. Small misfolded Tau species are internalized via bulk endocytosis and anterogradely and retrogradely transported in neurons. Wu JW, Herman M, Liu L, Simoes S, Acker CM, Figueroa H, Steinberg JI, Margittai M, Kayed R, Zurzolo C, Di Paolo G, Duff KE, J Biol Chem 2013 288 1856 1870 10.1074/jbc.M112.394528 23188818
50. Trans-cellular propagation of Tau aggregation by fibrillar species. Kfoury N, Holmes BB, Jiang H, Holtzman DM, Diamond MI, J Biol Chem 2012 287 19440 19451 10.1074/jbc.M112.346072 22461630
51. Seeding of normal Tau by pathological Tau conformers drives pathogenesis of Alzheimer-like tangles. Guo JL, Lee VM, J Biol Chem 2011 286 15317 15331 10.1074/jbc.M110.209296 21372138
52. Prion-like mechanisms in neurodegenerative diseases. Frost B, Diamond MI, Nat Rev Neurosci 2010 11 155 159 20029438
53. Mechanisms of protein seeding in neurodegenerative diseases. Walker LC, Diamond MI, Duff KE, Hyman BT, JAMA Neurol 2013 70 304 310 10.1001/jamaneurol. 2013.1453 23599928
54. Progress and developments in tau aggregation inhibitors for Alzheimer disease. Bulic B, Pickhardt M, Mandelkow E, J Med Chem 2013 56 4135 4155 10.1021/jm3017317 23484434
55. Synaptic alterations in the rTg4510 mouse model of tauopathy. Kopeikina KJ, Polydoro M, Tai HC, Yaeger E, Carlson GA, Pitstick R, Hyman BT, Spires-Jones TL, J Comp Neurol 2013 521 1334 1353 10.1002/cne.23234 23047530
56. Caspase activation precedes and leads to tangles. de Calignon A, Fox LM, Pitstick R, Carlson GA, Bacskai BJ, Spires-Jones TL, Hyman BT, Nature 2010 464 1201 1204 10.1038/nature08890 20357768
57. Characteristics and consequences of muscarinic receptor activation by tau protein. Gomez-Ramos A, Diaz-Hernandez M, Rubio A, Diaz-Hernandez JI, Miras-Portugal MT, Avila J, Eur Neuropsychopharmacol 2009 19 708 717 10.1016/j.euroneuro.2009.04.006 19423301
58. Extracellular tau promotes intracellular calcium increase through M1 and M3 muscarinic receptors in neuronal cells. Gomez-Ramos A, Diaz-Hernandez M, Rubio A, Miras-Portugal MT, Avila J, Mol Cell Neurosci 2008 37 673 681 10.1016/j.mcn.2007.12.010 18272392
59. The intersection of amyloid beta and tau in glutamatergic synaptic dysfunction and collapse in Alzheimer's disease. Crimins JL, Pooler A, Polydoro M, Luebke JI, Spires-Jones TL, Ageing Res Rev 2013 12 757 763 10.1016/j.arr.2013.03.002 23528367
60. Passive immunization with anti-Tau antibodies in two transgenic models: reduction of Tau pathology and delay of disease progression. Chai X, Wu S, Murray TK, Kinley R, Cella CV, Sims H, Buckner N, Hanmer J, Davies P, O'Neill MJ, Hutton ML, Citron M, J Biol Chem 2011 286 34457 34467 10.1074/jbc.M111. 229633 21841002
61. Passive immunization targeting pathological phospho-tau protein in a mouse model reduces functional decline and clears tau aggregates from the brain. Boutajangout A, Ingadottir J, Davies P, Sigurdsson EM, J Neurochem 2011 118 658 667 10.1111/j.1471-4159.2011.07337.x 21644996
62. Tau-targeted immunization impedes progression of neurofibrillary histopathology in aged P301L tau transgenic mice. Bi M, Ittner A, Ke YD, Gotz J, Ittner LM, PLoS One 2011 6 26860 10.1371/journal.pone.0026860 22174735
63. Developing therapeutic antibodies for neurodegenerative disease. Yu YJ, Watts RJ, Neurotherapeutics 2013 10 459 472 10.1007/s13311-013-0187-4 23549647
64. The neuropathology of frontotemporal lobar degeneration with respect to the cytological and biochemical characteristics of tau protein. Taniguchi S, McDonagh AM, Pickering-Brown SM, Umeda Y, Iwatsubo T, Hasegawa M, Mann DM, Neuropathol Appl Neurobiol 2004 30 1 18 10.1046/j.0305-1846.2003.00481.x 14720172 (Pubitemid 38177998)